Influenza, Human: all 2,264 studies

Page 21 of 23. Open to participants first (173), then studies with results posted, then the rest; newest registration first within each.

• Catechin Containing Mask for the Prevention of Influenza InfectionCompletedNCT00812448Not applicable
• Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)CompletedNCT00812019Phase 1
• Study of Maternal Hepatitis C Infection and Influenza Vaccination in PregnancyTerminatedNCT00810875
• Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type bCompletedNCT00808392Phase 3
• Evaluation of Efficacity and Safety of Oseltamivir and ZanamivirTerminatedNCT00799760Phase 3
• Study to Evaluate Nosocomial Transmission of InfluenzaStatus unknownNCT00798421
• Heterosubtypic Immune Responses to Influenza in Older PeopleCompletedNCT00798343Phase 1
• Direct and Indirect Benefits of Influenza Vaccine Versus Placebo in Healthy ChildrenCompletedNCT00792051Not applicable
• Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)CompletedNCT00783926Phase 1
• Influenza Vaccination in Immunocompromized PatientsCompletedNCT00783380Phase 4
• Immunogenicity and Tolerability Study of FluvalAB FL-K-004 Trivalent Influenza VaccineCompletedNCT00778297Not applicable
• Vaccine for Prevention of Bird FluCompletedNCT00776711Phase 1
• Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza VaccinesCompletedNCT00776438Phase 2
• Face Masks for Preventing Influenza TransmissionCompletedNCT00774774Phase 4
• High Dose Influenza in Immunosuppressed SubjectsWithdrawnNCT00766285Phase 2
• Influenza Vaccine in HIVCompletedNCT00764998Phase 3
• Surveillance of Influenza Virus Among Children With Febrile Respiratory Complaints Attending the Pediatric Clinic of the First Affiliated Hospital, Shantou University Medical College, Shantou, Guangdong, Mainland ChinaCompletedNCT00760500
• Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Lung Transplant RecipientsCompletedNCT00760175Not applicable
• Influenza Vaccination at a Reduced Dose Using Mesotherapy in HIV/AIDS Patients at the Hadassah AIDS Center, JerusalemStatus unknownNCT00758212Not applicable
• Efficacy of Influenza Vaccine in HIV Infected AdultsCompletedNCT00757900Phase 4
• Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.CompletedNCT00755703Phase 1
• Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy AdultsCompletedNCT00754455Phase 2
• Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2008/2009CompletedNCT00748813Phase 2
• Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009, When Administered to Non-Elderly Adult and Elderly SubjectsCompletedNCT00748150Phase 2
• Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2008/2009CompletedNCT00735410Phase 3
• Study to Evaluate Safety, Tolerability and Immunogenicity of a Bedside Mixing Combination of Two Adjuvanted Influenza VaccinesCompletedNCT00735020Phase 1
• Safety and Reactogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type bCompletedNCT00734565Phase 1
• Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine VaccineCompletedNCT00734175Phase 1
• Immuno & Reacto of TF Trivalent Influenza Split Vaccine 2003/04 or of Std Formulation Influsplit SSW®/Fluarix™ 2003/04CompletedNCT00731393Phase 3
• Reacto & Immunogenicity of TF Formulation of Influsplit SSW® 2002/03 v/s Std Formulation of Influsplit SSW® 2002/03CompletedNCT00731029Phase 3
• Phase 1 Safety and Immunogenicity Study in Healthy Adults of VAX125, a Recombinant HA-flagellin Influenza VaccineCompletedNCT00730457Phase 1
• Immunogenicity and Safety of GSK Biologicals' FluLaval® TFCompletedNCT00727428Phase 1
• Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB01L1 in Healthy VolunteersCompletedNCT00724997Phase 1
• Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus VaccineCompletedNCT00722774Phase 1
• Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 FormulationCompletedNCT00718146Phase 2
• Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk GroupsCompletedNCT00711295Phase 3
• Pandemic Influenza Plasmid DNA Vaccines (Needle)CompletedNCT00709800Phase 1
• Oseltamivir Randomised Controlled Efficacy TrialCompletedNCT00707941Phase 3
• A Safety and Immunogenicity Trial in Adults 65 Years of Age or Over to Prevent InfluenzaCompletedNCT00706732Phase 1/2
• Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in AdultsCompletedNCT00703651Phase 2
• A Study of the Safety, Tolerability & Immunogenicity of CSL Limited's Influenza Virus Vaccine In a Paediatric PopulationCompletedNCT00700193Phase 3
• Pandemic Influenza Plasmid DNA Vaccines (Needle-Free)CompletedNCT00694213Phase 1
• H5N1 (Clade 2) Vaccination of Adults and ElderlyCompletedNCT00680069Phase 1/2
• Cell-mediated Immune Response to Influenza VaccineCompletedNCT00677547
• Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 08/09 Season.CompletedNCT00665509Phase 3
• Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted VaccineCompletedNCT00664417Phase 1
• Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 AdjuvantCompletedNCT00662272Phase 1
• Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)VaccineCompletedNCT00660257Phase 1
• CS-8958 Single Inhaled Dose in ElderlyCompletedNCT00657111Phase 1
• Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 MonthsCompletedNCT00649883Phase 2
• Effect of the Interferon Alpha Citizen by Sub-Lingual Way on the Humoral Immunizing AnswerTerminatedNCT00647465Phase 3
• Immunogenicity and Safety Following a Single Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine (an Adjuvanted Sub-unit Influenza Vaccine and a Non-adjuvanted Split Virion Influenza Vaccine) in the Previous V70P2 StudyCompletedNCT00644540Phase 2
• A Prospective Study to Examine the Effectiveness and Safety of Antivirals in Volunteers Who Receive Short-term Prophylaxis Against Pandemic InfluenzaWithdrawnNCT00640874
• A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Index Cases With Presumed Pandemic InfluenzaWithdrawnNCT00640302
• A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Volunteers Who Receive Long-term Prophylaxis Against Pandemic Influenza: PIPET BWithdrawnNCT00640211
• FLU A+B Nasal Swab Clinical StudyCompletedNCT00636662
• Probiotics to Enhance Immunogenicity of Influenza Vaccine in Healthy AdultsCompletedNCT00620412Phase 1
• H9 Priming Study in Healthy AdultsCompletedNCT00617331Phase 2
• Pomegranate Products for Prevention of Common ColdCompletedNCT00617318Phase 3
• The Efficacy of Influenza Vaccination in Patients With Coronary Artery DiseasesCompletedNCT00607217Phase 2/3
• The Efficacy of Influenza Vaccine in Reducing Cardiovascular Events in Patients With Coronary Artery DiseasesCompletedNCT00607178Phase 2/3
• Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant SubjectsCompletedNCT00606359Phase 2
• Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy AdultsCompletedNCT00603811Phase 1
• Safety and Tolerability of a Cell-Derived Influenza Vaccine in Healthy Adults Aged ≥18 Years and ≤ 49 YearsCompletedNCT00599443Phase 1
• Influenza Vaccine in Pregnancy Part 2CompletedNCT00593970
• Early Oseltamivir Treatment of Influenza in Children 1-3 Years of AgeCompletedNCT00593502Phase 4
• Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza VaccineCompletedNCT00561184Phase 2
• Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu VaccineCompletedNCT00559975Phase 1
• A Pilot Study to Evaluate the Safety and Immunogenicity of Low Dose Flu VaccinesCompletedNCT00558649Not applicable
• Phase IV Clinical Trial of an Influenza Split Vaccine AnfluCompletedNCT00556062Phase 4
• Comparative Study of Immunogenicity and Safety of Flu-ID Vaccine Versus Flu-IM VaccineCompletedNCT00554333Phase 3
• Immune Response to Influenza VaccinationCompletedNCT00551837
• Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy AdultsCompletedNCT00546585Phase 1/2
• Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in AdultsCompletedNCT00545701Phase 2
• Impact of Immunosuppression in IBD Patients on Response to Influenza VaccineCompletedNCT00542776
• Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 YearsCompletedNCT00537524Phase 2
• Safety and Immunogenicity of an Inactivated Pandemic Influenza VaccineCompletedNCT00535665Phase 2
• Influenza in People With Normal and Weakened Immune SystemsCompletedNCT00533182
• A/H5N1 Dose Ranging Study With Adjuvant PatchCompletedNCT00532792Phase 1
• Testing a Personally Controlled Health Record to Ameliorate Influenza at MITCompletedNCT00531700Not applicable
• Safety and Immunogenicity Study of a Booster Vaccination With a Non-Adjuvanted H5N1 Influenza Vaccine (Follow Up to Study 810501)CompletedNCT00530660Phase 2
• Single Dose Escalating Study of DAS181 in AdultsCompletedNCT00527865Phase 1
• Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to Elderly SubjectsCompletedNCT00522236Phase 2
• Support Annual Strain Update, Safety and Immunogenicity of an Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008, When Administered to Subjects 18-64 Years Affected by Chronic Diseases.CompletedNCT00522067Phase 2
• Safety, Reactogenicity and Immunogenicity of an H5N1 VLPCompletedNCT00519389Phase 1/2
• Immunogenicity and Safety of an Adjuvanted Inactivated Subunit Influenza Vaccine to Those of a Non-adjuvanted Inactivated Subunit Influenza Vaccine, When Administered to Adults Affected by Chronic DiseasesCompletedNCT00519064Phase 3
• Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to NON Elderly AND Elderly SubjectsCompletedNCT00518726Phase 2
• Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine Formulation 2007-2008CompletedNCT00518453Phase 2
• Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)CompletedNCT00517517Phase 1/2
• Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy AdultsCompletedNCT00516035Phase 1
• A Phase III, Open-Label, Single-Dose Study to Evaluate the Safety and Immunogenicity of Fluviral® VaccineCompletedNCT00505453Phase 3
• Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2007/2008CompletedNCT00498303Phase 3
• Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in ChildrenCompletedNCT00491985Phase 2
• QuickVue Influenza A+B Clinical Field TrialCompletedNCT00491283Not applicable
• A Study of the Immunogenicity and Safety of the 2007-2008 Influenza VaccineCompletedNCT00491257Phase 2
• Intervention Study of Face Mask and Hand Sanitizer to Reduce Influenza TransmissionCompletedNCT00490633Not applicable
• Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given IntradermallyCompletedNCT00489931Phase 1
• Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy AdultsCompletedNCT00488046Phase 1
• Intramuscular Peramivir for the Treatment of Uncomplicated InfluenzaWithdrawnNCT00486980Phase 3
• Annual Study to Investigate Influenza Vaccine Due to New Virus Strains for the 2007/2008 Influenza Season in EuropeCompletedNCT00479921Phase 3

← Influenza, Human overview